At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Elobixibat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating Elobixibat and Placebo oral tablet for NAFLD and NASH. Completed, enrolled 47 participants across 10 sites.
Detailed Summary
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
Study Details
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedJul 2019
Primary CompletionJun 2020
Study CompletionJul 2020
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartJun 6, 2019
Primary CompletionJun 26, 2020
Study CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.0 years ago
Interventions
Elobixibatdrug
Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
Placebo oral tabletdrug
Placebo identical in appearance to active drug